The short version:
NAD+ is a molecule every cell needs to produce energy, and it genuinely does decline as we age — that part isn't hype, it's basic biochemistry. NMN and NR, the two popular supplement precursors, have real human trials showing they safely raise NAD+ levels in the blood and produce some measurable metabolic benefits. What they have not been shown to do is extend human lifespan — that evidence exists only in mice so far. The gap between "raises a biomarker" and "makes you live longer" is exactly where most of the marketing lives. Here's what's actually proven, what isn't, and how to think about it.
🎙️ Prefer to listen?
AI-generated audio overview — 24 min
🎙️ Audio overview generated with Google NotebookLM. Full written article below.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell in your body, and it's central to two things cells can't function without: converting food into usable energy (ATP) and activating a family of proteins called sirtuins, which help regulate DNA repair, inflammation, and cellular stress responses. Without adequate NAD+, mitochondria — the cell's energy factories — simply can't do their job as efficiently.
The well-established part of this story: NAD+ levels measurably decline with age across multiple tissues, including muscle, liver, and brain. Researchers point to two main drivers — reduced production through the body's natural NAD+-making pathway, and increased breakdown by an enzyme called CD38, which becomes more active as we get older. Less production plus faster consumption adds up to a real, measurable age-related decline.
This is where NMN (nicotinamide mononucleotide) and nicotinamide riboside (NR) come in. Both are precursor molecules — raw materials your body converts into NAD+ through a few enzymatic steps — sold as supplements on the premise that replenishing the raw material can restore youthful NAD+ levels. That premise, on its own, is reasonable biochemistry. The question is what actually happens when you test it in real people.
Unlike a lot of trendy longevity ingredients, NMN and NR aren't purely theoretical — both have real published human trials. Here's what they actually found, not what the marketing implies they found.
The first published human safety study on NMN, conducted in healthy Japanese men, tested single oral doses up to 500mg and found it was well tolerated with no significant changes in heart rate, blood pressure, oxygen saturation, body temperature, or reported gastrointestinal issues. This was a short, single-dose safety study — not a long-term outcomes trial — but it established the basic groundwork that later, longer trials have built on.
A randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults found that six weeks of nicotinamide riboside supplementation was well tolerated and effectively raised blood NAD+ levels compared to placebo. This is one of the better-designed human trials in the space, and it's genuinely useful evidence — it confirms these supplements do what they claim to do at the biomarker level: they raise NAD+.
A 10-week randomized, placebo-controlled trial in postmenopausal women with prediabetes found that 250mg/day of NMN improved skeletal muscle insulin sensitivity by roughly 25% compared to placebo, with no serious adverse effects reported. This is the most encouraging functional outcome in the human NMN literature so far — a real, measurable metabolic benefit, not just a shift in a blood marker. It's also a single trial in a specific population (postmenopausal women with prediabetes), so it doesn't automatically generalize to a healthy 30-year-old.
Here's the honest gap. The dramatic "longevity" headlines around NAD+ boosters trace back almost entirely to mouse studies, where NAD+ precursors have improved measures of physiological decline and, in some studies, extended lifespan. No published human trial has tested — or could realistically test on any near-term timeline — whether NMN or NR extends human lifespan. Raising a biomarker and improving one metabolic outcome in a clinical trial is real evidence. It is not the same claim as "this will help you live longer," and the industry's marketing routinely blurs that line.
Both NMN and NR are marketed as superior NAD+ precursors, and both have legitimate human trial data behind them, so the honest answer is that neither has a decisively proven edge over the other in humans. NMN has the more direct biochemical path to NAD+ (one fewer conversion step) and the insulin-sensitivity data above; NR has the longer track record of well-controlled human trials confirming it reliably raises blood NAD+ levels. If a company claims its specific form is dramatically superior based on cell-culture or mouse data alone, that's a marketing claim outrunning the human evidence — a pattern worth recognizing throughout this category.
I've sold a lot of "next big thing" longevity products over three decades, and NAD+ boosters are a rare case where the underlying biology is genuinely solid — NAD+ decline with age is real, well-documented science, not a marketing invention. Where I'd push back is on how the supplement is being sold to you.
If the marketing promises a longer life instead of "may support cellular energy metabolism," that's a sign the claim has outrun what's actually been shown in humans.
NAD+ decline with age is real, well-documented biology — not a marketing story. NMN and NR both have genuine human trial data showing they're safe at studied doses and reliably raise blood NAD+ levels, with one solid trial also showing a real metabolic benefit (improved muscle insulin sensitivity) in a specific population. That's meaningfully more evidence than most trendy longevity ingredients can claim.
What isn't there yet is proof that any of this translates into a longer human lifespan — that evidence currently exists only in mice. The honest way to approach this category: it's a legitimate, biomarker-backed supplement worth considering as part of a metabolic-health strategy, not a proven anti-aging solution. Anyone selling it to you as the latter is running ahead of the science, not reporting it.
1. Imai, S., & Guarente, L. (2016). It takes two to tango: NAD+ and sirtuins in aging/longevity control. npj Aging and Mechanisms of Disease, 2, 16017.
2. Irie, J., Inagaki, E., Fujita, M., et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153–160.
3. Martens, C.R., Denman, B.A., Mazzo, M.R., et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1), 1286.
4. Yoshino, M., Yoshino, J., Kayser, B.D., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229.
This article reflects the current published human research on NAD+ precursors. It is not personalized medical advice. Always consult your physician before starting any supplement, especially if you take other medications or have an existing health condition.